ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Milano, Lombardia, ITA:

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...

Active, not recruiting
Leukemia
Drug: Dasatinib

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Monza, Italy and 173 other locations

Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: revumenib
Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals
Syndax Pharmaceuticals

Milan, Italy and 56 other locations

(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 3

AstraZeneca
AstraZeneca

Milano, Italy and 108 other locations

this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias...

Enrolling
Accelerated Phase Chronic Myeloid Leukemia
Acute Lymphocytic Leukemia
Drug: Ponatinib

Phase 1, Phase 2

Incyte
Incyte

Milan, Italy and 32 other locations

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (C...

Active, not recruiting
Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Drug: Acalabrutinib

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

Milano, Italy and 11 other locations

The aim of this study is to support development of asciminib in the pediatric population (1 to \<18 years) previously treated with one or more TKIs....

Enrolling
Myeloid Leukemia, Philadelphia Positive
Drug: Asciminib Adult formulation group
Drug: Asciminib Pediatric formulation group

Phase 1, Phase 2

Novartis
Novartis

Monza, MB, Italy and 35 other locations

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...

Active, not recruiting
Myeloid Leukemia, Chronic, Chronic Phase
Drug: Ponatinib

Phase 2

Takeda
Takeda

Monza, Monza E Brianza, Italy and 85 other locations

The study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Acute Lymphoblastic Leukemia...

Active, not recruiting
B Cell Precursor Acute Lymphoblastic Leukemia
Drug: Blinatumomab

Phase 1, Phase 2

Amgen
Amgen

Milano, Italy and 42 other locations

This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN...

Active, not recruiting
Acute Myeloid Leukemia
Drug: IMGN632
Drug: Venetoclax

Phase 1, Phase 2

AbbVie
AbbVie

Milano, Italy and 30 other locations

participants with previously treated chronic phase - chronic myeloid leukemia (CP-CML).The study has two parts: Part 1 of the trial (Dose Es...

Enrolling
Chronic Myeloid Leukemia
Chronic Myeloid Leukemia, Chronic Phase
Drug: TERN-701

Phase 1

Terns Pharmaceuticals

Milano, Italy and 39 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems